Benazepril Hydrochloride Market

The Benazepril Hydrochloride market is witnessing a CAGR of 5.5% during the forecast period of 2025-2035. Benazepril hydrochloride is a chemically synthesized pharmacologic agent in the class of angiotensin-converting enzyme (ACE) inhibitors used for the majority to treat high blood pressure (hypertension) and congestive heart failure. Through inhibiting the enzyme ACE, benazepril curtails the generation of the peptide angiotensin II, which induces the constriction of blood vessels. This brings about vasodilation and drops in blood pressure, thus mitigating the stress placed on the heart and strengthening overall cardiovascular output.

In pharmacy, benazepril hydrochloride is used as the active component in different antihypertensive drugs. Benazepril hydrochloride has been formulated in several ways, including monotherapy and combination with diuretics such as hydrochlorothiazide, to maximize therapeutic effectiveness. The drugs are sold under various brand names, e.g., Lotensin. Clinical guidelines suggest a loading dose of 10 mg once a day in patients, not on a diuretic, and the usual maintenance dose is between 20-40 mg per day, taken either as a single dose or as two divided doses. At chronic therapy, maximum blood pressure reduction with a particular dose occurs after one to two weeks. Sudden withdrawal of benazepril has not been linked with an immediate rise in blood pressure.

Apart from human medicine, benazepril hydrochloride finds a place in veterinary medicine. It is used for conditions like canine heart failure and feline and canine chronic kidney disease. The European Medicines Agency (EMA) has assessed veterinary medicinal products based on benazepril hydrochloride, including Fortekor, realizing its position in animal health. Fortekor is available in different tablet dosages and types for use in dogs and cats to treat heart failure and chronic kidney disease.